Table 3.
Clinicopathologic characteristics of patients receiving palliative chemotherapy
| Characteristics (n = 13) | No of patient | % |
|---|---|---|
| Age, | Median: 59 (36-74) | |
| Sex | ||
| Male | 12 | 92.3% |
| Female | 1 | 7.7% |
| ECOG PS | ||
| 0-1 | 11 | 84.6 |
| 2 | 2 | 15.4 |
| Stage | ||
| Stage IV at diagnosis | 6 | 46.2% |
| Recurred cancer | 7 | 53.8% |
| Portal vein thrombosis | ||
| Yes | 8 | 61.5% |
| No | 5 | 38.5% |
| Metastasis | ||
| LN | 9 | 69.2% |
| Liver | 8 | 61.5% |
| Peritoneal seeding | 3 | 23.1% |
| Pancreas | 2 | 15.4% |
| lung | 1 | 7.7% |
| Gastrectomy | ||
| Yes | 10 | 76.9% |
| No | 3 | 23.1% |
| Number of metastatic organ | ||
| 1-2 | 8 | 61.5% |
| > 3 | 5 | 38.5% |
| Chemotherapy | ||
| Up to 1st line | 13 | 100% |
| Up to 2nd line | 7 | 53.8% |
| Up to 3rd line | 1 | 7.7% |
| Chemotherapeutic agent | ||
| FP/XP/FOLFOX† | 7 | 53.8% |
| TP‡ | 2 | 15.4% |
| TS-1 | 2 | 15.4% |
| Others (FL§, FM¶) | 2 | 15.4% |
†cisplatin and 5-FU/capecitabine and cisplatin/oxaliplatin, leucovorin and 5-FU
‡ paclitaxel and cisplatin
§ 5-FU and leucovorin
¶ 5-FU and MMC